Daniel Sanders, the lead researcher at Albert Labs, sat down with Proactive London to explain the company's use of mycelia in creating drug substances.
Many drug development companies will use synthetic versions of mycelia, but Sanders argues the benefits of the natural version.
The company is also in the process of filing a number of patent applications.